An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity.
about
Advanced vaccine candidates for Lassa feverVaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidateModulation of SIV and HIV DNA vaccine immunity by Fas-FasL signalingGenomic profiling of host responses to Lassa virus: therapeutic potential from primate to manVaccines for viral hemorrhagic fevers--progress and shortcomingsGenetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.Vaccine platforms to control Lassa fever.General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines.The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.Mammarenaviral Infection Is Dependent on Directional Exposure to and Release from Polarized Intestinal Epithelia.A vaccine platform against arenaviruses based on a recombinant hyper-attenuated Mopeia virus expressing heterologous glycoproteins.The S Genome Segment Is Sufficient to Maintain Pathogenicity in Intra-Clade Lassa Virus Reassortants in a Guinea Pig Model
P2860
Q26823627-8CEE24FD-B385-4C50-84DD-78EBD2E48B76Q33723534-19A965A5-7D56-402C-B6DA-14C46359CD0DQ34999818-2CCCDF7B-B35A-4000-8475-627A5C968420Q35232840-AFCAC9C6-FA9F-4EFF-88F3-AEA0887A04E6Q35248863-686F011F-2A65-42AB-8BC0-113814CB8A06Q37096221-B34C6BEB-6D3D-46EA-ACEE-2BF6069FBCB9Q37643724-BA271A33-1666-4F1E-97E0-75A4E1CB3882Q38818648-69865F04-36C0-4D95-BC7B-F53418D42BEEQ38823264-B89E02F6-1AE8-4D72-A504-7B0DCC94FEF3Q39097131-C97ABD5A-A081-41F3-A141-28D7B68673F3Q39602870-A30151E0-0244-4125-A1FD-0A48A623BC41Q44106019-DB696678-8849-4D81-851B-226963F60096Q50034248-9B3FEA0C-787B-4D1A-99ED-86B2565298B6Q52625005-90B970FD-7A27-4E75-A36D-29D64EF30525Q56913187-688FB099-D2FE-4E6F-B79C-35BE333EDB32
P2860
An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
An attenuated Lassa vaccine in ...... Lassa virus-specific immunity.
@ast
An attenuated Lassa vaccine in ...... Lassa virus-specific immunity.
@en
type
label
An attenuated Lassa vaccine in ...... Lassa virus-specific immunity.
@ast
An attenuated Lassa vaccine in ...... Lassa virus-specific immunity.
@en
prefLabel
An attenuated Lassa vaccine in ...... Lassa virus-specific immunity.
@ast
An attenuated Lassa vaccine in ...... Lassa virus-specific immunity.
@en
P2093
P2860
P356
P1433
P1476
An attenuated Lassa vaccine in ...... Lassa virus-specific immunity
@en
P2093
Bhawna Poonia
C David Pauza
Crystal Jaing
Dmitry Moshkoff
Eugene Ateh
Harry Davis
Igor S Lukashevich
Joseph Bryant
Lanea George
Marco Goicochea
P2860
P356
10.1186/1743-422X-10-52
P577
2013-02-12T00:00:00Z